Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib extension safety study in solid tumors
NL-OMON40491Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of veliparib in Nonhematologic neoplasms (3 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and tolerability, Objective response rate and 3 more. Started Jun 2014; status: active, not recruiting.
02
Drugs
veliparib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON40491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40491.